These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36804071)

  • 21. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
    Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
    CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
    Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S
    Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies.
    Emsley R; Parellada E; Bioque M; Herrera B; Hernando T; García-Dorado M
    Int Clin Psychopharmacol; 2018 Jan; 33(1):15-33. PubMed ID: 28817397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haloperidol discontinuation for people with schizophrenia.
    Essali A; Turkmani K; Aboudamaah S; AbouDamaah A; Diaa Aldeen MR; Marwa ME; AlMounayer N
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011408. PubMed ID: 31006114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.
    McCutcheon RA; Taylor D; Rubio J; Nour J; Pillinger T; Murray RM; Jauhar S
    Schizophr Bull; 2024 Apr; 50(3):513-520. PubMed ID: 37797288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis.
    Li Q; Li X; Ye C; Jia M; Si T
    CNS Drugs; 2023 Aug; 37(8):695-713. PubMed ID: 37490267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports.
    Hodkinson A; Heneghan C; Mahtani KR; Kontopantelis E; Panagioti M
    BMC Med; 2021 Aug; 19(1):195. PubMed ID: 34429113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
    Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
    Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
    Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
    Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
    CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.